MENU

DARE Stock Tickeron detected bullish Stock Pattern: Broadening Wedge Ascending DARE on April 15, 2025, netting in a 0.68% gain over 1 week

A.I.dvisor
at Tickeron.com
Loading...
+0.68% Gain from a Successful pattern Broadening Wedge Ascending
DARE - Dare Bioscience Inc.
Tickeron
Ticker: DARE
Company: Dare Bioscience
Gain: +0.68%
Confirmed: 04/15/25
Succeeded: 04/21/25
Total length: 12 days
On April 09, 2025, A.I.dvisor detected a Broadening Wedge Ascending Pattern (Bullish) for Dare Bioscience Inc. (DARE, $2.95). On April 15, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $3.02. 6 days later, on April 21, 2025, DARE reached the target price resulting in a for traders who took a long position in the stock.

DARE sees its Stochastic Oscillator climbs out of oversold territory

On April 10, 2025, the Stochastic Oscillator for DARE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on DARE as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DARE just turned positive on March 27, 2025. Looking at past instances where DARE's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

DARE moved above its 50-day moving average on April 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DARE advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DARE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DARE broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DARE entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.267) is normal, around the industry mean (14.056). P/E Ratio (0.099) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. DARE's P/S Ratio (2500.000) is slightly higher than the industry average of (252.992).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
DARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3655 Nobel Drive
Phone
+1 858 926-7655
Employees
26
Web
https://www.darebioscience.com